Hanmi Pharmaceutical's Targeted Anticancer New Drug Selected for National New Drug Development Project
[Asia Economy Reporter Seo So-jeong] Hanmi Pharmaceutical (CEO Kwon Se-chang and Woo Jong-su) announced on the 22nd that its dual inhibitor (HM97662) targeting the oncogenes EZH1 and EZH2, being developed as an innovative new drug for refractory malignant hematologic cancers and solid tumors, has been selected as a project under the National New Drug Development Foundation's national new drug development program.
This is the second selection following Hanmi Pharmaceutical's 'LAPS Glucagon Analog (HM15136),' which is being developed as an innovative new drug for congenital hyperinsulinism and was selected for a 28-month research funding support project last November. The national new drug development program is a government-wide R&D project that supports the entire drug development cycle based on an open innovation strategy involving pharmaceutical companies, academia, research institutes, and hospitals.
With the national research funding support for HM97662, Hanmi Pharmaceutical plans to promptly complete the ongoing preclinical development and accelerate entry into the clinical phase.
The epigenetic gene EZH2 is an oncogene that is mutated or overexpressed in many relapsed or refractory cancer types that currently have no treatment or are difficult to treat with existing anticancer therapies. However, selective inhibition of EZH2 leads to compensatory activation of EZH1, causing resistance; therefore, an inhibitor that simultaneously suppresses both EZH2 and EZH1 is necessary.
According to Hanmi Pharmaceutical, HM97662 demonstrated strong anticancer effects by dual inhibition of EZH1 and EZH2 through preclinical studies.
Hot Picks Today
At President Lee's Call to "Give Enough to Shock," Whistleblower Rewards Become a Real Lottery
- If They Fail Next Year, Bonus Drops to 97 Million Won... A Closer Look at Samsung Electronics DS Division’s 600M vs 460M vs 160M Performance Bonuses
- 'Emperor of Wall Street' Dimon: "Hiring More AI Experts, Reducing Bank Teller Jobs"
- Opening a Bank Account in Korea Is Too Difficult..."Over 150,000 Won in Notarization Fees Just for a Child's Account and Debit Card" [Foreigner K-Finance Status]②
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
Kwon Se-chang, CEO of Hanmi Pharmaceutical, stated, "Hanmi's new drug development for treating refractory and resistant patients who do not respond to existing drugs can now enter clinical trials more quickly thanks to this research funding support."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
